Gabapentin Enacarbil Patent Expiration

Gabapentin Enacarbil is used for managing postherpetic neuralgia in adults and treating moderate-to-severe primary restless leg syndrome in adults. It was first introduced by Azurity Pharmaceuticals Inc in its drug Horizant on Apr 6, 2011.


Gabapentin Enacarbil Patents

Given below is the list of patents protecting Gabapentin Enacarbil, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Horizant US8795725 GABA analog prodrug sustained release oral dosage forms Jun 10, 2029 Azurity
Horizant US8026279 Crystalline form of γ-aminobutyric acid analog Nov 10, 2026 Azurity
Horizant US8114909 Treating or preventing restless legs syndrome using prodrugs of GABA analogs Apr 11, 2026 Azurity
Horizant US6818787 Prodrugs of GABA analogs, compositions and uses thereof Apr 06, 2025 Azurity
Horizant US8686034 Crystalline form of γ-aminobutyric acid analog Jan 24, 2025 Azurity
Horizant US8048917 Prodrugs of GABA analogs, compositions and uses thereof Nov 06, 2022

(Expired)

Azurity



Gabapentin Enacarbil's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List